Tags : Thermo Fisher

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics […]Read More

PharmaShots Weekly Snapshot (March 09-13, 2020)

1. I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19 Published: Mar 13, 2020 | Tags: I-Mab, Initiate, Development, TJM2, Treating, Cytokine Release Syndrome, COVID-19 2. EMD Serono and Pfizer to Terminate P-III JAVELIN Head and Neck 100 Study Evaluating Bavencio + CRT for Squamous Cell Carcinoma of the Head […]Read More

Thermo Fisher Collaborates with NanoPin to Facilitate Infectious Diseases Diagnosis

Shots: The companies collaborated to develop highly sensitive liquid chromatography-mass spectrometry (LC-MS)-based workflows for advancing blood-based infectious disease detection technology  The collaboration leverages NanoPin’s diagnostic platform and Thermo Fisher’s LC-MS technology to develop clinical assays for infectious disease for determining infection stage and monitor patient response to treatment The collaboration may lead to a change […]Read More

Thermo Fisher to Expand its Clinical Trials Capabilities and Collaborates

Shots: Thermo Fisher expands its clinical trials supply and distribution services network in China with the investment of $4.4M in its Suzhou facility to support the growth of clinical studies and to provide biotech companies with the resources to develop and commercialize new therapies in China Additionally, Thermo Fisher collaborates with Frontier to expedite the […]Read More

Eli Lilly Signs an Agreement with Thermo Fisher to Develop

Shots: The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with Lilly’s LOXO-292 Thermo Fisher will retain rights to commercialize its test in all markets including the US, EU and Japan. Post validation, Thermo Fisher will […]Read More

Thermo Fisher Enters into a Collaboration with Genome Canada and

Shots: Thermo Fischer signs a 3yrs. collaboration with Genome Canada and the Ontario Institute for Cancer Research (OICR) to develop targeted next-generation sequencing-based assays and analysis software for $6M. Genome to fund $2M for development & validation which will split b/w Thermo Fischer and OICR  The partners will develop one assay for diagnosis of pancreatic […]Read More

Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Shots: Thermo Fisher acquires a manufacturing facility in Ireland from GSK for ~$100M cash to develop & commercialize APIs for multiple diseases including childhood cancer, depression and Parkinson’s. The transaction is expected to close in H2’19 including regulatory approvals The focus of the acquisition is to expand Thermo Fischer’s APIs manufacturing capabilities. Under a multi-year […]Read More

Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays

Shots: Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal’s NeXosome platform with Thermo Fisher’s LC-MS instrumentation for monitoring the maternal & fetal health and evaluating the risk of complications The focus of the collaboration is to provide a diagnostic solution to both clinical and medical professionals […]Read More